A Study of ZN-c3 in Participants With Solid Tumors

Conditions:   Solid Tumor;   Epithelial Ovarian Cancer;   Fallopian Tube Cancer;   Peritoneal Cancer;   Triple Negative Breast Cancer;   Small Cell Lung Cancer;   Metastatic Breast Cancer;   Malignant Melanoma;   Non Small Cell Lung Cancer;   Urothelial Carcinoma Interventions:   Drug: ZN-c3;   Drug: Talazoparib;   Drug: Pembrolizumab Sponsors:   K-Group Beta;   IQVIA Biotech Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials

Related Links:

Publication date: Available online 12 December 2019Source: The LancetAuthor(s): Jack Cuzick, Ivana Sestak, John F Forbes, Mitch Dowsett, Simon Cawthorn, Robert E Mansel, Sibylle Loibl, Bernardo Bonanni, D Gareth Evans, Anthony Howell, IBIS-II investigatorsSummaryBackgroundTwo large clinical trials have shown a reduced rate of breast cancer development in high-risk women in the initial 5 years of follow-up after use of aromatase inhibitors (MAP.3 and International Breast Cancer Intervention Study II [IBIS-II]). Here, we report blinded long-term follow-up results for the IBIS-II trial, which compared anastrozole with placebo...
Source: The Lancet - Category: General Medicine Source Type: research
Publication date: Available online 11 December 2019Source: Best Practice &Research Clinical Endocrinology &MetabolismAuthor(s): Giusy Elia, Silvia Martina Ferrari, Maria Rosaria Galdiero, Francesca Ragusa, Sabrina Rosaria Paparo, Ilaria Ruffilli, Gilda Varricchi, Poupak Fallahi, Alessandro AntonelliAbstractAnticancer immunotherapy, in the form of immune checkpoint inhibition (ICI), is a paradigm shift that has transformed the care of patients with different types of solid and hematologic cancers. The most notable improvements have been seen in patients with melanoma, non-small-cell lung, bladder, renal, cervical, u...
Source: Best Practice and Research Clinical Endocrinology and Metabolism - Category: Endocrinology Source Type: research
CONCLUSIONS: sDC-HIL in the blood and probably DC-HIL receptor expressed by MDSC plays an important role in regulating response to ICI in advanced NSCLC. PMID: 31822499 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research
Publication date: Available online 22 October 2019Source: Seminars in Cancer BiologyAuthor(s): Tamara T. Lah, Metka Novak, Barbara BreznikAbstractBrain, the major organ of the central nervous system controls and processes most of body activities. Therefore, the most aggressive brain tumor – glioblastoma and metastases from other organs to the brain are lethal leaving the patients with very short time of survival. The brain tissue landscape is very different from any other tissues and the specific microenvironment, comprising stem cells niches and blood-brain barrier, significantly influences the low rate of glioblast...
Source: Seminars in Cancer Biology - Category: Cancer & Oncology Source Type: research
Publication date: Available online 2 December 2019Source: Life SciencesAuthor(s): Yu-kun Li, Juan Zou, Dong-mei Ye, Ying Zeng, Chang-ye Chen, Gui-fang Luo, Xi ZengAbstractAn oncogenic role, p21-activated kinase 5 (PAK5), has proven as a significant mediator for many cellular progression, which is expressed highly in human organs such as lung, liver, kidney, blood vessels endothelial cells and inflammatory cells. PAK5 was primitively detected in the cerebrum and accelerated the filopodia formation in neurocytes. It can reverse the effect of Rho and adjust its activity to mediate maintenance and development of nerve axon by ...
Source: Life Sciences - Category: Biology Source Type: research
In this study, using melanoma and NSCLC cells, we demonstrate that ALDH3A1 isozyme overexpression and activity is closely associated with a highly aggressive mesenchymal and immunosuppressive profile. The contribution of ALDH3A1 to the stemness and immunogenic status of melanoma and NSCLC cells was evaluated by their ability to grow in 3D forming tumorspheres, and by the expression of markers for stemness, epithelial to mesenchymal transition (EMT), and inflammation. Furthermore, in specimens from melanoma and NSCLC patients, we investigated the expression of ALDH3A1, PD-L1, and cyclooxygenase-2 (COX-2) by immunohistochemi...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
This article is protected by copyright. All rights reserved
Source: Biotechnology and Applied Biochemistry - Category: Biochemistry Authors: Tags: Original Article Source Type: research
Publication date: Available online 4 December 2019Source: Genes &DiseasesAuthor(s): Wei Wang, Zhao-Hui WuAbstractUltraviolet radiation (UVR) is a prominent etiological factor of the pathogenesis of skin diseases such as squamous cell carcinoma and melanoma. Excessive exposure to the natural sources of UVR such as sunlight or artificially from tanning lamps has been linked to the increasing incidence of skin cancers in the United States. Besides the skin inflammation, DNA damage and oncogenic mutation caused by UVR, UV exposure also plays a critical role in suppressing local and systemic immune responses which enable pr...
Source: Genes and Diseases - Category: Genetics & Stem Cells Source Type: research
CONCLUSIONS: Tremelimumab monotherapy demonstrated clinical activity and durable responses in patients with metastatic urothelial carcinoma. This study is the first in which CR has been observed with tremelimumab as a single agent in urothelial carcinoma. PMID: 31801732 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research
AbstractBackgroundParaneoplastic syndromes (PNS) are autoimmune disorders specifically associated with cancer. There are few data on anti-PD-1 or anti-PD-L1 immunotherapy in patients with a PNS. Our objective was to describe the outcome for patients with a pre-existing or newly diagnosed PNS following the initiation of anti-PD-1 or anti-PD-L1 immunotherapy.MethodsWe included all adult patients (aged ≥18) treated with anti-PD-1 or anti-PD-L1 immunotherapy for a solid tumor, diagnosed with a PNS, and registered in French pharmacovigilance databases. Patients were allocated to cohorts 1 and 2 if the PNS had been diagnosed ...
Source: Journal for Immunotherapy of Cancer - Category: Cancer & Oncology Source Type: research
More News: Biotechnology | Cancer | Cancer & Oncology | Carcinoma | Melanoma | Research | Skin Cancer | Study